Thanks for this report, the info provided feeds into my Q to Alterity.
It states 70% of pts in the european countries have MSA-P while Japan only has 30%, interesting.
Given the 201 study was across the globe, including the countries named, it would now be interesting to see where the 70% of the MSA-P study group on the 75mg trial were from.
In addition to this, MSA-P has more parkinsonian resemblance than MSA-C, which will play excellently for a play into earlier treatment/diagnosis of MSA and PD as they are hard to differentiate early (except maybe now with the other a-syn skin result).
Anyways, commentators are talking about a flashing red market sign with Bonds hitting 5%, so bit of upcoming turbulence ahead, nice to have some spare change around it there is a decent dip.
Anyways, above is MOO, DYOR, dont follow me, because most of the time im lost and going in circles trying to find the right path.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)